Natera (NASDAQ:NTRA) Releases Earnings Results, Beats Expectations By $0.31 EPS

Natera (NASDAQ:NTRA) released its quarterly earnings data on Tuesday. The medical research company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.31, Briefing.com reports. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter in the previous year, the business posted ($0.95) EPS. Natera’s revenue for the quarter was up 63.9% on a year-over-year basis. Natera updated its FY 2024 guidance to EPS.

Natera Trading Down 6.1 %

Shares of NASDAQ NTRA opened at $151.11 on Friday. The business’s 50 day moving average is $126.71 and its 200-day moving average is $115.09. The company has a current ratio of 4.39, a quick ratio of 4.01 and a debt-to-equity ratio of 0.33. Natera has a 1-year low of $52.01 and a 1-year high of $167.79.

Insider Buying and Selling

In related news, CFO Michael Burkes Brophy sold 608 shares of the stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $120.76, for a total transaction of $73,422.08. Following the sale, the chief financial officer now owns 74,014 shares of the company’s stock, valued at $8,937,930.64. This represents a 0.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 5,024 shares of Natera stock in a transaction on Monday, September 16th. The shares were sold at an average price of $128.48, for a total value of $645,483.52. Following the completion of the transaction, the chief executive officer now directly owns 195,686 shares of the company’s stock, valued at $25,141,737.28. This represents a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,881 shares of company stock valued at $3,733,983. Insiders own 7.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on NTRA shares. Sanford C. Bernstein raised their target price on shares of Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. BTIG Research raised their price objective on shares of Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Craig Hallum upped their target price on shares of Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday. Morgan Stanley increased their target price on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, TD Cowen boosted their price target on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a report on Wednesday. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $137.65.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.